Sat Kartar Life Ltd
Sat Kartar Life Q2 Results 2026 (FY27) investor presentation: Revenue & Margins
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
Sat Kartar Life Ltd Q2 FY27 key numbers
- Revenue
- Reported revenue from operations for the quarter ended September 30, 2026 (unaudited consolidated) is Rs. 11,387.49 lakhs.
As stated in Sat Kartar Life Ltd's Q2 FY27 investor presentation · published 25 Oct 2026. Reported figures, not investment advice.
Based on Sat Kartar Life Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Reported revenue from operations for the quarter ended September 30, 2026 (unaudited consolidated) is Rs. EBITDA for the quarter ended Sep 30, 2026: Rs.
From Sat Kartar Life Ltd's Q2 FY27 earnings-call transcript · updated 25 Oct 2026.
Revenue & Sales Performance
- Reported revenue from operations for the quarter ended September 30, 2026 (unaudited consolidated) is Rs. 11,387.49 lakhs (Page 8).
- Revenue for the quarter ended September 30, 2025 was Rs. 9,007.11 lakhs (Page 8).
- This represents a year-on-year revenue increase of approximately 26.43% [(11,387.49 - 9,007.11)/9,007.11 * 100].
- The presentation does not provide explicit volume or sales quantity figures.
- No explicit forward-looking revenue or volume outlook is stated in the provided pages of the presentation.
2 more points from Sat Kartar Life Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
- EBITDA for the quarter ended Sep 30, 2026: Rs. 1,233.27 lacs (Unaudited consolidated, Page 8)
- Year-on-year EBITDA change:
- Sep 30, 2025 EBITDA was Rs. 1,010.79 lacs (Page 8)
- Increase of Rs. 222.48 lacs (~22%)
- Operating Margin is not explicitly stated; calculated from Revenue and EBITDA:
- Revenue Sep 30, 2026: Rs. 11,430.57 lacs (Page 8)
- Operating Margin ≈ (1,233.27 / 11,430.57) * 100 ≈ 10.8%
- Profit After Tax (PAT) for the quarter: Rs. 924.90 lacs (Consolidated, Page 8)
- Year-on-year PAT change:
- Sep 30, 2025 PAT was Rs. 729.98 lacs (Page 8)
2 more points from Sat Kartar Life Ltd's call on margins
Pro opens every point from 15K+ earnings calls
Capital Expenditure Plans
- Ayurveda Hospital Capital Expenditure: Rs. 33.80 crores allocated; as of Sept 30, 2026, Rs. 25.82 crores utilized, Rs. 7.98 crores unutilized; no deviation reported.
- Healthcare Establishment and Expansion: Rs. 28.26 crores utilized out of Rs. 29.16 crores allocated; Rs. 0.90 crores unutilized; no deviation.
- Strategic Acquisitions and Global Expansion: Rs. 6.39 crores allocated and fully utilized; no deviation.
- Technology, Branding, and Market Expansion: Rs. 8.75 crores allocated, Rs. 3.00 crores utilized, Rs. 5.75 crores unutilized; no deviation.
- General Corporate Purpose: Rs. 2.92 crores allocated, Rs. 0.30 crores utilized, Rs. 2.62 crores unutilized; no deviation.
2 more points from Sat Kartar Life Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
Read what Sat Kartar Life Ltd said on fundraising in the Q2 FY27 call
Free account with your mobile number. We text a one-time code, no password.
Continue your research
What Sat Kartar Life Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Torrent Pharmaceuticals Ltd (Q2 FY27)
4,979 crores, up 51% YoY (Page 23). Key results statement takeaways from Torrent Pharmaceuticals Ltd's Q2 FY27 results statement — and how it ranks against sect
- Sakar Healthcare Ltd (Q2 FY27)
2,985.57 lakh (approximately 51.9% growth) . Key results statement takeaways from Sakar Healthcare Ltd's Q2 FY27 results statement — and how it ranks against se
- Dr Reddys Laboratories Ltd (Q2 FY27)
Reported Q2FY27 revenues: ₹8,671 Cr, up 1.5% YoY and 7% QoQ (Page 4). Key investor presentation takeaways from Dr Reddys Laboratories Ltd's Q2 FY27 investor pre
- Beta Drugs Ltd (Q2 FY27)
H1 FY25: ₹180 Crs . Key investor presentation takeaways from Beta Drugs Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.
Arthneeti Pro · Annual
Sat Kartar Life Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Sat Kartar Life Ltd Q2 FY27 results?
Reported revenue from operations for the quarter ended September 30, 2026 (unaudited consolidated) is Rs. EBITDA for the quarter ended Sep 30, 2026: Rs.
What is Sat Kartar Life Ltd share price analysis?
Sat Kartar Life Ltd currently shows a neutral. The stock trades at a P/E of 13.0 with a market cap of ₹206 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sat Kartar Life Ltd planning capital expenditure?
Ayurveda Hospital Capital Expenditure: Rs.
Keep Sat Kartar Life Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.